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Research
Arsenic is abundant in the earth’s crust and 
can be released to groundwater under certain 
conditions. It has been estimated that 13 mil-
lion Americans have been exposed to pub-
lic water supplies with 10–50 µg/L arsenic 
(U.S. EPA 2000, 2001). In Bangladesh, more 
than 50 million people have been chronically 
exposed to drinking groundwater with arsenic 
concentrations exceeding the World Health 
Organization standard (10 µg/L) (British 
Geological Survey 1999). In many parts of 
the world where groundwater is an important 
source of drinking water, exposure to inor-
ganic arsenic (InAs) from drinking water has 
been linked to increased risks of skin cancer 
(Hsueh et al. 1997), internal cancers such as 
bladder, lung, and liver cancers (Chen et al. 
1988, 2004a), and cardiovascular disease 
(Chen et al. 1995, 1996). In addition, sys-
tematic reviews of the literature on the asso-
ciation between arsenic exposure and diabetes 
mellitus suggest a possible role of high arsenic 
exposure (> 500 µg/L) in diabetes mellitus 
(Chen et al. 2007; Navas-Acien et al. 2006).
However, the effects of exposure to lower 
concentrations of arsenic on diabetes are 
unclear. In a cross-sectional study of 1,185 
residents in Wisconsin, Zierold et al. (2004) 
calculated odds ratios (ORs) for diabetes of 
1.4 [95% confidence interval (CI), 0.8–2.3] 
and 1.1 (95% CI, 0.5–2.2) for arsenic expo-
sure levels of 2–10 µg/L and > 10 µg/L, 
respectively, with the referent group < 2 µg/L. 
Compared with that of the general popula-
tion in Utah, Lewis et al. (1999) found that 
the standard mortality ratio for diabetes was 
not elevated among members of a Mormon 
community in Millard County, Utah, with 
< 200 µg/L of arsenic in drinking water. In 
a case-control study in Mexico, the ORs for 
diabetes were 1.9 (95% CI, 1.1–3.4) and 2.7 
(95% CI, 1.5–4.6) for groups with total uri-
nary arsenic of 64–104 µg/L and > 104 µg/L, 
respectively (Coronado-Gonzalez et al. 2007). 
More recently, in a cross-sectional study from 
National Health and Nutrition Examination 
Survey (NHANES), Navas-Acien et al. (2008) 
reported that the OR for diabetes was 3.6 
(95% CI, 1.2–10.8) when they compared par-
ticipants at the 80th percentile with those at 
the 20th percentile for urinary arsenic (16.5 
vs. 3.0 µg As/L). Several reanalyses of the same 
data, as well as updated data with more sub-
jects from NHANES, suggest that opposing 
results may be explained by differences in how 
urinary creatinine and arsenobetaine (AsB) in 
the urine were handled in the statistical mod-
eling (Longnecker 2009; Navas-Acien et al. 
2009; Steinmaus et al. 2009a, 2009b). Given 
this controversy, studies in populations with 
long-term arsenic exposure at 10–300 µg/L 
are important in justifying future studies of 
arsenic exposure at lower levels.
In addition, to better understand the 
pathophysiology and mechanism by which 
arsenic exposure may lead to diabetes, stud-
ies of biomarkers for manifestations of dia-
betes are needed. Glycosylated hemoglobin 
(HbA1c) is the result of the nonenzymatic 
glycosylation of hemoglobin, which reflects 
the integrated blood glucose level during the 
preceding 3–4 months; to meaure HbA1c, 
fasting is not necessary. Although several stud-
ies have suggested that suboptimal arsenic 
methylation capacity, which was indicated by 
a relatively high proportion of monomethylar-
sonic acid (MMA) in urine, is positively asso-
ciated with the risk for health effects of arsenic 
exposure such as the risk of skin and bladder 
cancer (Hsueh et al. 1997; Kopp 2005; Yu 
et al. 2000), the relationship between arsenic 
methylation capacity and HbA1c is unknown.
We established a study of 11,746 indi-
viduals in Araihazar, Bangladesh, in the year 
2000 to assess arsenic-related health effects. 
We conducted cross-sectional analyses to 
evaluate the associations of arsenic exposure 
with diabetes status and glucosuria. In a sub-
set of 2,100 participants, we also assessed the 
relationship of arsenic exposure and the com-
position of urinary arsenic metabolites with 
HbA1c levels.
Methods
The Health Effects of Arsenic Longitudinal 
Study (HEALS). The parent study HEALS 
is an ongoing prospective cohort study in 
Araihazar, Bangladesh. Details of the study 
methodologies have been presented elsewhere 
(Ahsan et al. 2006a; Parvez et al. 2006). Prior 
to subject recruitment, water samples and 
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Ba c k g r o u n d: The long-term effects of arsenic exposure from drinking water at levels < 300 µg/L 
and the risk of diabetes mellitus remains a controversial topic. 
Me t h o d : We conducted a population-based cross-sectional study using baseline data from 11,319 
participants in the Health Effects of Arsenic Longitudinal Study in Araihazar, Bangladesh, to evalu-
ate the associations of well water arsenic and total urinary arsenic concentration and the prevalence 
of diabetes mellitus and glucosuria. We also assessed the concentrations of well water arsenic, 
total urinary arsenic, and urinary arsenic metabolites in relation to blood glycosylated hemoglobin 
(HbA1c) levels in subsets of the study population.
re s u l t s: More than 90% of the cohort members were exposed to drinking water with arsenic 
concentration < 300 µg/L. We found no association between arsenic exposure and the prevalence of 
diabetes. The adjusted odds ratios for diabetes were 1.00 (referent), 1.35 [95% confidence interval 
(CI), 0.90–2.02], 1.24 (0.82–1.87), 0.96 (0.62–1.49), and 1.11 (0.73–1.69) in relation to quintiles 
of time-weighted water arsenic concentrations of 0.1–8, 8–41, 41–91, 92–176, and ≥ 177 µg/L, 
respectively, and 1.00 (referent), 1.29 (0.87–1.91), 1.05 (0.69–1.59), 0.94 (0.61–1.44), and 0.93 
(0.59–1.45) in relation to quintiles of urinary arsenic concentrations of 1–36, 37–66, 67–114, 
115–204, and ≥ 205 µg/L, respectively. We observed no association between arsenic exposure and 
prevalence of glucosuria and no evidence of an association between well water arsenic, total urinary 
arsenic, or the composition of urinary arsenic metabolites and HbA1c level.
co n c l u s i o n s: Our findings do not support an association of arsenic exposure from drinking water 
and a significantly increased risk of diabetes mellitus in the range of levels observed. Further pro-
spective studies would be valuable in confirming the findings.
key w o r d s : arsenic exposure, Bangladesh, cross-sectional studies, diabetes, environmental epi-
demiology. Environ Health Perspect 118:1299–1305 (2010).  doi:10.1289/ehp.0901559 [Online 
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their geographic coordinates were collected for 
5,966 contiguous wells in a well-defined geo-
graphic area of 25 km2 in Araihazar. Between 
October 2000 and May 2002, 11,746 men 
and women ≥ 18 years of age were recruited, 
with a response rate of 97.5% (Ahsan et al. 
2006a). Verbal informed consent was 
obtained from study participants. The study 
procedures were approved by the Columbia 
University Institutional Review Board and the 
Ethical Committee of the Bangladesh Medical 
Research Council.
At baseline recruitment, lifestyle and 
demographic information were collected using 
structured interviews. Trained study physicians 
measured height and weight using a locally 
manufactured tape measure and a Misaki 
(Okaka, Japan) scale (calibrated weekly), 
respectively. Both height and weight were 
measured three times at baseline and aver-
aged. Venous whole blood samples were col-
lected for 91.8% of the overall 11,746 cohort 
participants in 3-mL vacutainers containing 
EDTA as anticoagulant. A spot urine sample 
was collected in 50-mL acid-washed tubes for 
95.6% of the cohort participants. Both blood 
and urine samples were kept in portable cool-
ers immediately after collection and were pro-
cessed within 2–8 hr and transferred to –20°C 
freezers before being shipped to Columbia 
University on dry ice within 1–2 months.
Measurements of arsenic exposure. At base-
line, water samples from all 5,966 tube wells 
in the study area were collected in 50-mL acid-
washed tubes after well pumping for 5 min 
(van Geen et al. 2002, 2003). Total arsenic 
concentration was determined by graphite fur-
nace atomic-absorption spectrometry (GFAA) 
with a Hitachi Z-8200 system (Hitachi 
Corp., Tokyo, Japan) (van Geen et al. 2002). 
Samples that fell below the detection limit of 
GFAA (5 µg/L) were subsequently analyzed by 
inductively coupled plasma mass spectrometry 
(ICP-MS), with a detection limit of 0.1 µg/L 
(Cheng et al. 2005). All participants were pri-
mary users of one of the 5,966 tube wells, 
desig  nated as the “index” well, for at least 3 
years. We derived a time-weighted arsenic 
concentration (TWA) as a function of drink-
ing durations and well arsenic concentrations 
[TWA (micrograms per liter) = Σ CiTi/Σ Ti, 
where Ci and Ti denote the well arsenic con-
centration and drinking duration for the ith 
well] (Ahsan et al. 2006b). The average dura-
tion of well use for wells with a known arsenic 
concentration accounted for 25% of lifetime 
for both sexes (Ahsan et al. 2006b).
Total urinary arsenic concentration 
was measured by GFAA, using a Perkin-
Elmer AAnalyst 600 graphite furnace system 
(PerkinElmer, Waltham, MA, USA) with 
a detection limit of 2 µg/L, as previously 
described (Nixon et al. 1991). Urinary creati-
nine was analyzed using a method based on the 
Jaffe reaction for adjusting urinary total arsenic 
concentration (Slot 1965). All the urine sam-
ples were detectable for total urinary arsenic.
As part of case–control and case–cohort 
studies of other health outcomes (Ahsan et al. 
2007), urinary arsenic metabolites were meas-
ured in a random 10% of HEALS participants 
using a method described by Reuter et al. 
(2003). This method employs HPLC separation 
of AsB, arsenocholine (AsC), AsV, AsIII, MMA, 
and dimethylarsinic acid (DMA), followed by 
detection by ICP-MS with dynamic reaction 
cell (ICP-MS-DRC), with a detection limit of 
0.2 µg/L for AsB and AsC and of 0.1 µg/L for 
all other metabolites. Arsenic methylation indi-
ces including the percentage of InAs, MMA, 
and DMA of the total urinary arsenic were cal-
culated after subtracting AsB and AsC (i.e., 
nontoxic organic arsenic from dietary sources) 
from the total. We also constructed two meth-
ylation indices: primary methylation index 
(PMI), that is, the ratio of MMA to InAs and 
the secondary methylation index (SMI), that is, 
the ratio of DMA to MMA.
Measurement of dietary intakes. Dietary 
intakes were measured at baseline with a 
validated semiquantitative food frequency 
questionnaire (FFQ) designed for the study 
population. Detailed information on the 
design and the validation of the FFQ has been 
published elsewhere (Chen et al. 2004b). The 
results of the validation study indicate that 
the FFQ can provide reasonably valid meas-
urements for long-term dietary intakes of 
common foods, macronutrients, and common 
micronutrients (Chen et al. 2004b).
Diabetes‑related outcomes. This study is 
a cross-sectional analysis using the baseline 
data of the HEALS. At baseline, interviewers 
recorded generic names of all medicines that 
the study participants were taking regularly. 
At the first 2-year follow-up, participants were 
asked if they had ever been diagnosed by a 
physician with diabetes, and date of diagnosis 
was ascertained for those who gave a positive 
answer. The study physicians and interviewers 
were blinded to urinary arsenic and well water 
arsenic levels (Ahsan et al. 2006b). Because 
baseline interviews did not include questions 
on diabetes status, we retrospectively iden-
tified participants who had a self-reported 
physician diagnosis of diabetes prior to base-
line. Those with a date of diagnosis earlier 
than the baseline interview date were defined 
as prevalent cases; cases diagnosed between 
baseline and first follow-up visit (n = 37) were 
excluded from the study. All the regular users 
of insulin or oral hypoglycemic medication 
reported that they had a physician diagnosis 
of diabetes. All the participants < 20 years old 
at baseline were excluded to focus on type 2 
diabetes as the disease of interest.
Blood samples from the first 2,100 con-
secutively recruited participants were analyzed 
for HbA1c. The percentage of HbA1c was 
measured by the Helena Glyco-Tek affin-
ity column method (Helena, Beaumont, 
TX, USA) using a Lambda UV/ViS spectro-
photometer (PerkinElmer). This is an affin-
ity microchromatographic methodology that 
quantitates all glycated hemoglobin, including 
the A1c fraction, and is not subject to interfer-
ence by labile glycated hemoglobin (Klenk 
et al. 1982). The HbA1c value was deter-
mined by comparing the two solutions using a 
spectro  photometer operating at 415 nm.
At baseline, dipstick urinalysis was per-
formed by a trained physician on freshly evac-
uated spot urine samples using the Chemstrip 
Micral Test Strips (Roche Diagnostics, 
Indianapolis, IN, USA). The results of the 
urine test were based on a color scale that 
quantified glucosuria as negative, 50 mg/dL, 
100 mg/dL, 200 mg/dL, 500 mg/dL, and 
1,000 mg/dL.
Statistical analysis. We first conducted 
descriptive analyses comparing participants 
with diabetes and those without diabetes at 
baseline in terms of sociodemographic charac-
teristics, established risk factors of type 2 diabe-
tes, dipstick glucosuria, and HbA1c levels. We 
estimated ORs for diabetes and for glucosuria 
in relation to quintiles of arsenic exposure vari-
ables using unconditional logistic regression. 
Because treatments for diabetes may influence 
glucosuria status, participants with diabetes 
were excluded from those who tested negative 
for glucosuria in estimating ORs for gluco-
suria (n = 90). Established risk factors of diabe-
tes that may influence health effects of arsenic 
as indicated in previous studies (Ahsan et al. 
2006b; Argos et al. 2007; Chen et al. 2006) 
were considered as potential confounders. The 
associations between potential confounders 
and arsenic exposure variables are shown in 
Supplemental Material, Table 1 (doi:10.1289/
ehp.0901559). We first adjusted for age (years), 
sex (men and women), and body mass index 
(BMI; kilograms per meter squared), and in 
a separate model we additionally adjusted for 
smoking status (never, past, and current), and 
educational attainment (years). To evaluate the 
extent by which the association between arsenic 
exposure and diabetes could be attributable to 
arsenic content in foods, we also adjusted the 
ORs for intakes of fish and rice (grams per day) 
because fish can accumulate organic arsenic, 
which may influence total urinary arsenic con-
centration, and because rice may contain InAs 
from the soil (Das et al. 2004). In addition, 
Pearson correlation was used to evaluate the 
relative validity of total urinary arsenic and uri-
nary metabolites in assessing well water arsenic 
exposure and the extent to which fish and rice 
intakes contribute to total urinary arsenic.
Because BMI is a strong risk factor for 
diabetes, we conducted stratification analy-
sis to evaluate the associations of arsenic Arsenic exposure and diabetes
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exposure with diabetes and glucosuria in high 
and low BMI category, which was defined 
by the median value in the overall popula-
tion. Significance of multiplicative interaction 
between BMI and arsenic exposure was deter-
mined by the p-values associated with cross-
product terms for the dichotomized BMI and 
quintiles of arsenic exposure expressed as an 
ordinal variable in multivariate logistic mod-
els. Additional stratification was conducted for 
age and sex.
In addition, we estimated the ratio of geo-
metric means of arsenic exposure compar-
ing diabetics and nondiabetics using linear 
regression models on log-transformed arsenic 
levels. Sensitivity analyses were conducted to 
estimate the ratio of geometric means of arse-
nic exposure comparing the presence of both 
diabetes and glucosuria with absence of both 
conditions.
Arsenic concentrations measured in spot 
urine samples may be affected by the varia-
tion in dilution due to variation in the state 
of hydration. However, prevalent cases of dia-
betes have a lower level of urinary creatinine 
compared with noncases (Barr et al. 2005; 
de Fine et al. 2006), because they may have 
been hypercatabolic for a long period, which 
results in a smaller muscle mass and therefore 
diminished urinary creatinine (de Fine et al. 
2006). Diabetes-related hyperfiltration could 
also lead to a low level of creatinine and an 
increased urine volume (Mogensen 1994), 
which would result in differences in urinary 
creatinine-adjusted arsenic concentrations. 
Adjustment for factors affected by the disease 
may lead to bias away from the null in epide-
miologic studies and therefore is not recom-
mended (Greenland 2003). Nevertheless, 
because adjusting urinary arsenic concentra-
tion for the excretion of urinary creatinine is 
a common way of correcting the variation in 
dilution (Nermell et al. 2008), we show results 
with and without adjustment for urinary crea-
tinine in separate models.
To evaluate the association between arse-
nic exposure and HbA1c concentration, we 
computed least squares means of HbA1c level 
according to arsenic exposure categories using 
linear regression. Model construction proce-
dures were similar to those for logistic regres-
sion. The relationship between urinary arsenic 
methylation indices and HbA1c was assessed 
in 368 subjects who were part of both the 10% 
random selection of the overall study popula-
tion (for whom urinary arsenic metabolites 
were measured) and the first 2,100 enrolled 
subjects (who were tested for HbA1c). Results 
in the analyses of HbA1c excluding those with 
diabetes (n = 45) were similar and therefore 
are not shown.
In all analyses, controlling or excluding 
cases with skin lesions did not materially affect 
the results, and therefore these results are not 
shown. All analyses were peformed using SAS 
9.1.3 (SAS Institute Inc., Cary, NC, USA). 
All tests were two sided, and p < 0.05 was 
  considered significant.
Results
Participants who reported a diagnosis of dia-
betes prior to baseline (n = 241) were older 
and more likely to be past cigarette smokers, 
have higher blood pressure and lower levels of 
urinary creatinine, and have higher levels of 
BMI, urinary glucose, and HbA1c than were 
those who did not report a diagnosis of dia-
betes (n = 11,078) (Table 1). Only 1% of the 
individuals without diabetes tested positive on 
urinary glucose, whereas 61% of the individu-
als with diabetes tested positive (p < 0.01). In 
a subgroup of 2,100 participants, the median 
of HbA1c level was 6.8% in participants with 
diabetes, substantially higher than the median 
level among participants without diabetes 
(4.9%, p < 0.01). Diabetes was also positively 
related to betel nut use and indices of socio-
economic status in rural Bangladesh includ-
ing educational attainment, TV ownership, 
and land ownership (p < 0.01). These data 
were consistent with studies in rural areas in 
Bangladesh (Abu et al. 1995, 1997; Sayeed 
et al. 2003). Bivariate analysis also shows that 
the medians of well water arsenic and urinary 
arsenic concentration were slightly higher 
in noncases of diabetes compared with cases 
(62.0 µg/L vs. 53.0 µg/L for well water arse-
nic and 45.9 µg/L vs. 44.1 µg/L for urinary 
  arsenic, respectively).
In the overall analysis, we found no evi-
dence for an association between either TWA 
or urinary arsenic concentration and the 
prevalence of diabetes (Table 2). Multivariate 
adjustment for potential confounders had 
Table 1. Distribution of demographic, lifestyle, and arsenic exposure variables by diabetes status.
Diabetes
Variablea Yes (n = 241) No (n = 11,078)  p-Valueb
Men [n (%)] 120 (49.8) 4,736 (42.8) 0.03
Age (years) 42 (30, 56) 36 (25, 50) < 0.01
Education attainment (years) 5 (0, 10) 2 (0, 10) < 0.01
TV ownership [n (%)] 124 (51.5) 3,746 (33.8) < 0.01
Land ownership [n (%)] 161 (67.1) 5,424 (49.0) < 0.01
Cigarette-smoking status [n (%)]
Never 157 (65.2) 7,152 (64.6) < 0.01
Past 29 (12.0) 717 (6.5)
Current 55 (22.8) 3,209 (28.9)
Ever users of betel nut [n (%)] 111 (46.1) 4,220 (37.4) 0.01
Dietary intake of rice (g/day) 1,461 (519, 2,070) 1,554 (1,035, 2,101) < 0.01
Dietary intake of fish (g/day) 50 (21, 99) 47 (17, 98) 0.20
Systolic blood pressure (mmHg) 122 (100, 151) 112 (95, 136) < 0.01
Diastolic blood pressure (mmHg) 80 (65, 97) 73 (60, 89) 0.02
BMI (kg/m2) 22.5 (17.6, 26.7) 19.2 (16.3, 24.0) < 0.01
≥ 20 [n (%)] 54 (22.9) 5,467 (50.5) < 0.01
< 20 [n (%)] 182 (77.1) 5,356 (49.5)
Urinary creatinine (mg/dL)c 44.1 (15.9, 102.2) 45.9 (14.6, 120.1) 0.03
Arsenic concentration of index well (µg/L) 53.0 (1.2, 236.0) 62.0 (1.3, 264.0) 0.08
TWA (µg/L) 53.0 (1.3, 258.0) 62.0 (1.7, 255.2) 0.33
0.1–8.0 [n (%)] 52 (22.0) 2,206 (20.6) 0.50
8.1–41.0 [n (%)] 53 (22.5) 2,098 (19.6)
41.2–91.7 [n (%)] 49 (20.8) 2,102 (19.7)
91.8–176.1 [n (%)] 38 (16.1) 2,151 (20.1)
176.2–864.0 [n (%)] 45 (18.6) 2,140 (20.0)
Urinary arsenic concentration (µg/L)c 72.0 (23, 274) 87.0 (23, 311) 0.08
1–36 50 (21.5) 2,160 (20.4)
37–66 58 (24.9) 2,071 (19.6)
67–114 46 (19.7) 2,126 (20.1)
115–204 43 (18.5) 2,110 (19.9)
≥ 205 36 (15.5) 2,126 (20.1)
Creatinine-adjusted urinary arsenic (µg/g creatinine)c 175.7 (66.5, 536.8) 200.0 (62.5, 598.9) < 0.01
Urinary glucose (mg/dL)d [n (%)]
Negative 90 (39.0) 10,407 (99.1) < 0.01
50 23 (10.0) 39 (0.4)
100 14 (6.1) 16 (0.2)
≥ 200 104 (44.9) 35 (0.3)
HbA1c (%)e 6.8 (4.7, 10.9) 4.9 (4.4, 5.4) < 0.01
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure. Values shown are median (10th percentile, 
90th percentile) except where indicated.
aData were missing for the following variables:  BMI (5 cases and 255 noncases); education (0 and 6 subjects); TV 
ownership (0 and 2 subjects); rice intake (0 and 18 subjects); fish intake (5 and 131 subjects); blood pressure (2 and 237 
subjects); and TWA (5 and 381 subjects). bp‑Values from the chi‑square test or t‑test. cBased on 233 cases and 10,593 
noncases with urine samples and total urinary arsenic analysis results. dBased on 231 cases and 10,497 noncases with 
urine samples and urine glucose dipstick test results that were available. eBased on a subgroup of 45 diabetes cases 
and 1,999 noncases.Chen et al.
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little impact on the effect estimates, although 
associations between urinary arsenic and dia-
betes prevalence were stronger (but not sig-
nificant) after adjusting for urinary creatinine 
(Model 3). Associations also were not evident 
when the analysis was restricted to partici-
pants known to have more than 4 years of 
exposure (average = 11.2 years) from the well 
used to determine their TWA [Supplemental 
Material, Table 2 (doi:10.1289/ehp. 
0901559)]. No association was found between 
arsenic exposure and diabetes prevalence 
within categories of BMI, although the num-
ber of cases among those with low BMI (< 20, 
n = 67–71) was limited. Stratification by age 
(< 35 years and ≥ 35 years at baseline) and 
sex also did not suggest any subgroup-specific 
associations [Supplemental Material, Table 2 
(doi:10.1289/ehp.0901559)].
The correlation of well water arsenic with 
total urinary arsenic, DMA, and MMA con-
centration was 0.70, 0.61, and 0.57, respec-
tively. These results indicate a good relative 
validity of urinary arsenic as a reflection of 
arsenic exposure from well water. The cor-
relation between rice intake and total uri-
nary arsenic was 0.03 and 0.04 among the 
overall study population and in those with 
baseline well water arsenic < 50 µg/L, respec-
tively. Among the 10% random sample of the 
cohort with data on urinary arsenic metabo-
lites, the correlation between rice intake and 
urinary DMA concentration was 0.01 and 
0.02 among the overall and those with base-
line well water arsenic < 50 µg/L, respectively. 
The correlation of total urinary arsenic con-
centration with urinary AsB and AsC con-
centration were 0.13 and 0.06, respectively. 
These data suggest that rice and seafood 
intakes contributed very little to total urinary 
arsenic and urinary DMA concentration in 
the study population. Effect estimates of ORs 
for diabetes in relation to arsenic exposure 
did not change appreciably with additional 
adjustment for fish and rice intake (data not 
shown) [Supplemental Material, Table 2 
(doi:10.1289/ehp.0901559)].
Results of linear regression analyses also 
indicate that persons with diabetes had arsenic 
exposure levels similar to those without dia-
betes. In models adjusted for age, sex, BMI, 
smoking status, and educational attainment, 
the ratio of geometric means of arsenic expo-
sure comparing cases and noncases was 1.00 
(95%, 0.78–1.29), 0.96 (95%, 0.84–1.09), 
and 1.06 (95%, 0.95–1.19) for TWA, total 
urinary arsenic, and urinary creatinine-adjusted 
arsenic, respectively. In sensitivity analyses 
comparing diabetics with glucosuria (n = 141) 
and nondiabetics with negative urine glucose 
test (n = 10,407), ratios of geometric mean 
for TWA, total urinary arsenic, and urinary 
creatinine-adjusted arsenic were 1.10 (95% CI, 
0.79–1.52), 0.91 (95% CI, 0.77–1.07), and 
1.04 (95% CI, 0.91–1.20), respectively.
We observed no association between 
either TWA or urinary arsenic concentration 
and glucosuria in the overall study population 
(Table 3). Associations also were not evident 
among participants with categories of BMI 
levels defined by the median value. Additional 
adjustment for urinary creatinine did not 
change the estimates appreciably.
We also found no evidence of an asso-
ciation between arsenic exposure and HbA1c 
[Supplemental Material, Table 3 (doi:10.1289/
ehp.0901559)]. The adjusted means of HbA1c 
among participants with different levels of 
TWA and urinary arsenic were similar. Among 
the 368 participants with data on both uri-
nary arsenic metabolites and HbA1c, there 
was no evidence that HbA1c levels differed by 
%MMA, %InAs, or %DMA, nor did HbA1c 
levels differ by PMI or SMI. The associations 
were not significant in any individual catego-
ries or trend tests.
Discussion
In this large cross-sectional study of arsenic 
exposure and diabetes-related outcomes, we 
found that arsenic exposure, measured using 
either TWA or urinary arsenic concentra-
tion, was not related to diabetes, glucosuria, 
or blood HbA1c level.
The availability of data on environmental 
exposure to arsenic is a strength of the present 
study. Unlike previous studies of lower-level 
arsenic exposure, which lacked reproduc-
ible and valid measures of arsenic exposure 
and/or information on the nature of the expo-
sure (Lewis et al. 1999; Navas-Acien et al. 
2008; Zierold et al. 2004), our study popu-
lation was well described with detailed data 
on the duration, source, and form of expo-
sure. The average durations of well use for 
Table 2. Associations [OR (95% CI)] between arsenic exposure and diabetes.
Quintiles
Arsenic exposure variable 1 2 3 4 5 p for trenda
TWA (µg/L) 0.1–8.0 8.1–41.0 41.2–91.7 91.8–176.1 176.2–864.0
n (cases/noncases) 52/2,206 53/2,098 49/2,102 38/2,151 44/2,140
Model 1b 1.00 1.28 (0.85–1.91) 1.20 (0.80–1.81) 0.95 (0.61–1.47) 1.08 (0.71–1.65) 0.95
Model 2c 1.00 1.35 (0.90–2.02) 1.24 (0.82–1.87) 0.96 (0.62–1.49) 1.11 (0.73–1.69) 0.33
Urinary arsenic (µg/L) 1–36 37–66 67–114 115–204 ≥ 205
n (cases/noncases) 50/2,160 58/2,071 46/2,126 43/2,110 36/2,126
Model 1b 1.00 1.29 (0.87–1.91) 0.99 (0.65–1.50) 0.90 (0.59–1.39) 0.87 (0.56–1.36) 0.09
Model 2c 1.00 1.29 (0.87–1.91) 1.05 (0.69–1.59) 0.94 (0.61–1.44) 0.93 (0.59–1.45) 0.14
Model 3d 1.00 1.44 (0.97–2.17) 1.20 (0.77–1.85) 1.16 (0.73–1.85) 1.22 (0.73–2.03) 0.83
High BMI (BMI ≥ 20)e
TWA (µg/L)
n (cases/noncases) 39/883 32/803 32/805 27/797 35/740
Model 2c 1.00 1.02 (0.63–1.67) 1.01 (0.62–1.65) 0.86 (0.51–1.42) 1.13 (0.70–1.82) 0.72
Urinary arsenic (µg/L)
n (cases/noncases) 35/879 39/850 31/824 35/803 26/729
Model 2c 1.00 1.16 (0.72–1.87) 1.01 (0.61–1.68) 1.14 (0.70–1.87) 1.06 (0.62–1.80) 0.70
Model 3d 1.00 1.35 (0.83–2.21) 1.17 (0.69–1.98) 1.46 (0.85–2.51) 1.41 (0.77–2.59) 0.41
Low BMI (BMI < 20)e
TWA (µg/L)
n (cases/noncases) 13/1,323 21/1,295 17/1,297 11/1,354 9/1,400
Model 2c 1.00 1.74 (0.86–3.49) 1.35 (0.65–2.79) 0.83 (0.37–1.87) 0.66 (0.28–1.56) 0.07
Urinary arsenic (µg/L)
n (cases/noncases) 15/1,281 19/1,221 15/1,302 8/1,307 10/1,397
Model 2c 1.00 1.53 (0.75–3.12) 1.11 (0.52–2.34) 0.51 (0.20–1.27) 0.70 (0.30–1.60) 0.07
Model 3d 1.00 1.62 (0.79–3.34) 1.23 (0.56–2.69) 0.59 (0.22–1.55) 0.87 (0.34–2.25) 0.15
aEstimated using arsenic exposure as a continuous variable in the model. bModel 1: ORs were adjusted for age, sex, and BMI. cModel 2: ORs were adjusted for age, sex, BMI, smoking 
status, and educational attainment. dModel 3: ORs were adjusted for age, sex, BMI, smoking status, educational attainment, and urinary creatinine. ep‑Values for interaction between 
arsenic exposure and BMI were 0.76 (for well water arsenic, Model 2), 0.90 (for urinary arsenic, Model 2), and 0.89 (for urinary arsenic, Model 3). Arsenic exposure and diabetes
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wells with a known arsenic concentration were 
10.0 years for men and 8.3 years for women. 
With chronic and continuing exposure, 
steady-state concentrations in blood and urine 
are achieved. Well-water arsenic was corre-
lated with total urinary arsenic, urinary DMA, 
and urinary MMA concentration in our study 
population (of 0.70, 0.61, and 0.57, respec-
tively) and was clearly the primary source of 
arsenic in the urine. In NHANES, urinary 
concentration of nontoxic AsB and total uri-
nary arsenic were highly correlated with each 
other (r = 0.80) (Navas-Acien et al. 2008). On 
the contrary, consumption of seafood contrib-
uted very little to total urinary arsenic in our 
study population. Correlations of total urinary 
arsenic with urinary MMA and DMA con-
centrations (0.90 and 0.98, respectively) were 
much higher than with urinary AsB and AsC 
(0.13 and 0.06, respectively); AsB and AsC 
accounted for only 3% of total urinary arsenic 
in our study population.
HbA1c is a valid and reliable biomarker for 
long-term blood glucose level and is strongly 
associated with diabetes and prediabetes (Buell 
et al. 2007; Herman et al. 2000; Rohlfing et al. 
2000). Two other studies have evaluated dif-
ferences in HbA1c in relation to arsenic expo-
sure. Hansen et al. found that HbA1c level was 
elevated in taxidermists and workers working 
with arsenic-impregnated wood (Jensen and 
Hansen 1998). However, the study was small, 
with 40 workers and 26 controls, and the levels 
of occupational arsenic exposure were high. 
In the recent NHANES analysis, Navas-Acien 
et al. (2008), found no association between 
total urinary arsenic and HbA1c.
Animal and in vitro model systems have 
indicated that arsenic exposure can potentially 
increase the risk of diabetes through its effects 
on the inhibition of insulin-dependent glu-
cose uptake (Walton et al. 2004) and insulin 
signaling (Paul et al. 2007), impairment of 
insulin secretion and transcription in pancre-
atic beta cells (Diaz-Villasenor et al. 2006), 
and modification of the expression of genes 
involved in insulin resistance (Diaz-Villasenor 
et al. 2007). However, the concentrations used 
in most mechanistic experiments are high, 
and the observed effects may not be applicable 
to populations chronically exposed to arsenic 
in the environment. Nevertheless, the epide-
miologic literature suggests that diabetes is an 
adverse outcome associated with prolonged 
exposure to high levels of water arsenic (> 500 
µg/L). For instance, in a cross-sectional study 
of 1,595 subjects in Bangladesh, Rahman et al. 
(1999) reported an OR for diabetes of 1.7 
(95% CI, 1.0–2.9) comparing arsenic expo-
sure of > 10,000 µg/L-years to the unexposed 
group among those free of skin lesion. Among 
patients with skin lesions, a marker of pro-
longed exposure, the OR for diabetes in associ-
ation with 500–1,000 µg/L and > 1,000 µg/L 
was 2.2 (95% CI, 1.3–3.8) and 2.6 (95% CI, 
1.5–4.6), respectively (Rahman et al. 1999). 
In a cohort study with 41 incident cases of 
diabetes in southwestern Taiwan, the OR was 
2.1 (95% CI, 1.1–4.2) comparing individuals 
with cumulative arsenic exposure > 17,000 
µg/L-years to those with < 17,000 µg/L-years 
(Tseng et al. 2000). We did not find evidence 
of an association even when comparing the 
highest quintile of exposure (176–864 µg/L; 
mean, 291.2 µg/L) with the lowest (0.1–8 
µg/L; mean, 2.4 µg/L). As 90% of our study 
population was exposed to well water arsenic 
< 300 µg/L, the absence of an association in 
this study suggests that the effects of arsenic 
exposure on the risk of diabetes levels between 
10 and 300 µg/L are not significant. Taken 
together, the experimental and epidemiologic 
evidence suggests that the adverse effects on 
diabetes may be dose specific and limited to 
populations with prolonged exposure to very 
high levels of arsenic exposure.
The ratios of MMA/InAs and DMA/
MMA in urine are indicative of efficiency 
for the first and second methylation steps, 
respectively, and they have been related to the 
risk of an array of arsenic-related health effects 
including the risk of skin cancer (Chen et al. 
2003a; Hsueh et al. 1997; Yu et al. 2000), 
urothelial carcinoma (Pu et al. 2007), blad-
der cancer (Chen et al. 2003b), skin lesions 
(Ahsan et al. 2007), and hypertension (Huang 
et al. 2007). We found that HbA1c levels did 
not differ by the composition or absolute lev-
els of urinary arsenic metabolites, which sug-
gests that arsenic methylation capacity does 
not influence the risk of diabetes.
Several methodological issues should be 
noted in interpreting the results of our study. 
Similar to past reports on the topic, diabetes 
status was ascertained using self-report of a 
Table 3. Associations [OR (95% CI)] between arsenic exposure and glucosuria.a
Quintiles
Arsenic exposure variables 1 2 3 4 5 p for trendb
TWA (µg/L) 0.1–8.0 8.1–41.0 41.2–91.7 91.8–176.1 176.2–864.0
n (cases/noncases) 52/2,099 44/2,015 44/1,961 41/1,983 48/1,985
Model 1c 1.00 1.02 (0.67–1.55) 1.09 (0.72–1.65) 1.01 (0.66–1.54) 1.18 (0.78–1.77) 0.28
Model 2d 1.00 1.07 (0.71–1.63) 1.12 (0.74–1.71) 1.01 (0.66–1.56) 1.20 (0.79–1.81) 0.30
Urinary arsenic (µg/L) 1–36 37–66 67–114 115–204 ≥ 205
n (cases/noncases) 59/2,118 50/2,032 42/2,088 37/2,079 42/2,074
Model 1c 1.00 0.90 (0.61–1.34) 0.74 (0.49–1.12) 0.63 (0.41–0.97) 0.84 (0.56–1.27) 0.31
Model 2d 1.00 0.91 (0.62–1.34) 0.79 (0.52–1.19) 0.65 (0.43–1.01) 0.91 (0.60–1.37) 0.46
Model 3e 1.00 0.95 (0.63–1.42) 0.85 (0.55–1.31) 0.72 (0.45–1.15) 1.03 (0.63–1.68) 0.90
High BMI (BMI ≥ 20)
TWA (µg/L)
n (cases/noncases) 43/849 28/779 29/764 32/743 35/694
Model 2d 1.00 0.78 (0.45–1.38) 0.83 (0.51–1.35) 0.93 (0.58–1.50) 1.03 (0.65–1.65) 0.60
Urinary arsenic (µg/L)
n (cases/noncases) 46/855 37/828 26/804 30/790 30/703
Model 2d 1.00 0.80 (0.51–1.27) 0.60 (0.36–1.01) 0.67 (0.41–1.08) 0.87 (0.54–1.41) 0.50
Model 3e 1.00 0.84 (0.53–1.33) 0.64 (0.38–1.08) 0.73 (0.43–1.24) 0.96 (0.55–1.69) 0.87
Low BMI (BMI < 20)
TWA (µg/L)
n (cases/noncases) 9/1,250 16/1,236 15/1,197 9/1,240 13/1,291
Model 2d 1.00 1.93 (0.85–4.39) 1.82 (0.79–4.18) 1.03 (0.40–2.61) 1.45 (0.62–3.42) 0.82
Urinary arsenic (µg/L)
n (cases/noncases) 13/1,263 13/1,204 16/1,284 7/1,289 12/1,371
Model 2d 1.00 1.03 (0.47–2.23) 1.19 (0.57–2.50) 0.50 (0.20–1.26) 0.88 (0.40–1.94) 0.54
Model 3e 1.00 1.00 (0.53–2.49) 1.15 (0.53–2.49) 0.47 (0.18–1.26) 0.82 (0.33–2.04) 0.54
aBecause treatments for diabetes may influence glucosuria status, participants with diabetes were excluded from those who tested negative for glucosuria in estimating ORs for gluco‑
suria (n = 90). bEstimated using arsenic exposure as a continuous variable in the model. cModel 1: ORs were adjusted for age, sex, and BMI. dModel 2: ORs were adjusted for age, sex, 
BMI, smoking status, and educational attainment. eModel 3: ORs were adjusted for age, sex, BMI, smoking status, educational attainment, and urinary creatinine.Chen et al.
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physician’s prior diagnosis. To the extent that 
diabetes status was misclassified, the associa-
tion between arsenic exposure and diabetes 
prevalence could have been underestimated. 
Sensitivity analyses with cases restricted to 
diabetes with glucosuria did not alter associa-
tions between arsenic exposure and diabetes 
prevalence, which suggests that associations 
would not be specific to severe cases of dia-
betes. A continuum of risk for the develop-
ment of diabetes based on HbA1c levels has 
been demonstrated (Droumaguet et al. 2006; 
Edelman et al. 2004). Thus, the lack of trend 
in HbA1c levels and glucosuria prevalence 
across categories of arsenic exposure further 
indicate no association with diabetes in this 
study. Diabetes is a complex metabolic disor-
der. Because individuals with diabetes may also 
have altered xenobiotic metabolism and excre-
tion, the utility of using urinary arsenic concen-
trations as the biomarker of exposure could be 
limited (Kile and Christiani 2008). Steinmaus 
et al. (2009a, 2009b) suggested that creati-
nine adjustment may be one of the reasons for 
the strong association observed in NHANES 
data. Analogously, Gamble et al. have reported 
that correlation between urinary arsenic and 
plasma folate may due in part to the corre-
lation between folate and urinary creatinine 
(Gamble and Liu 2005). Given the potential 
limitation in the utility of urinary creatinine in 
retrospective case–control and cross-sectional 
studies, further prospective studies would be 
valuable. Finally, our study population in gen-
eral was lean with regard to low socioeconomic 
and nutritional status. Thus, the findings may 
not be generalizable to other study popula-
tions, given the possible different distribution 
of risk factors for diabetes that may influence 
the effect of arsenic exposure.
In conclusion, we did not find an asso-
ciation between arsenic exposure from drink-
ing water and diabetes-related outcomes. 
Although it is important to minimize arsenic 
exposure because of the increased risk of can-
cer and many other health effects, our study 
indicates that arsenic exposure, in the range 
of levels observed, does not pose a significant 
risk for diabetes.
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